Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This phase Ib/II trial tests the safety and side effects of grapiprant and eribulin and
whether they work to shrink tumors in patients with inflammatory breast cancer that has
spread to other places in the body (metastatic). Grapiprant is an anti-inflammatory drug that
may prevent tumor growth. Eribulin may block tumor cell growth by stopping tumor cell
division. Giving grapiprant and eribulin together may help to control the disease.